mimetics
BioAge Signs Option Agreement for Obesity Asset from Chinese Biotech Following APJ Agonist Setback
BioAge; JiKang Therapeutics; obesity; APJ agonist; option agreement; nanobody; small molecule agonists; exercise mimetic; incretin therapy; metabolic diseases
PRISM BioLab and Elix Collaborate to Revolutionize AI-Driven Drug Discovery with Peptide Mimetics
PRISM BioLab , Elix , AI drug discovery , Peptide mimetics , Protein-protein interactions , PepMetics® , Small molecule inhibitors , Drug discovery efficiency , Pharmaceutical innovation